It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. Is Ocugen Stock Still Worth Buying After Its 800%-Plus Rally? Analyst 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. If OCU300 is approved, theres a reasonably large market. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. For investors new to the story, there are some positives when it comes to OCGN stock. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. Ocugen Inc. Announces Closing of $100 Million Registered Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. The content is intended to be used for informational purposes only. It has real management. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. Not an offer or recommendation by Stocktwits. You never know when they will suddenly go on a squeeze. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. However, sometimes the optimism isn't justified. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. Ocugen stock jumps following positive Covid vaccine study results 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. Please check your download folder. Type a symbol or company name. It's hard to say for sure. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Ocugen Inc. is a clinical stage biopharmaceutical company. OCGN does not even appear to have an apparent reason to exist. Part of the proceeds will be used to support its partnership with Bharat. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. For priority reviews, the timeline for an approval decision is reduced to six months. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Custom BMW. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. Ocugen. Most biotech companies have intriguing stories on paper; Ocugen is no different. But the allure of the space is that when a company wins, its shareholders win big. Theres even room for more lines. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. To make the world smarter, happier, and richer. In this case, shares rallied about four-fold in just a few days. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Unfortunately for longs, OCGN is much closer to the worst of conditions. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Its worth emphasizing: Ocugen stock is a play with enormous risk. The average Ocugen stock price for the last 52 weeks is 2.10. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. See disclosure here. These symbols will be available throughout the site during your session. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Written by This decision. This decision isn't surprising, considering that Ocugen previously abandoned the pursuit of an EUA path for the vaccine in adults. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. So far, that merger hasnt worked out for Histogenics former shareholders. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. 1125 N. Charles St, Baltimore, MD 21201. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Ocugen to Present at the 2018 BIO International Convention | Ocugen, Inc. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. How long might it take for Ocugen to win full FDA approval for Covaxin? The odds of Ocugen stock winding up at zero are material. Our 3 Top Picks. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. The FDA's decision not to issue EUA really wasn't all that surprising, though. While anything is possible, I would not anticipate a miracle here. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. Written by The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Why Ocugen Stock Is Crushing It Today | Nasdaq It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. It has no treatments to offer the market. Ocugen had to go an unusual route to go public. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. Why Ocugen Stock Dropped Today | The Motley Fool - Nasdaq Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. These symbols will be available throughout the site during your session. Lorem ipsum dolor sit amet, consectetur adipiscing elit. For now, though, what happens in India stays in India. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." Investing is always a game of balancing risk and reward. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. Literally, zero. The short answer is: everything. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. Why Ocugen Stock Is Crashing Today | The Motley Fool - Nasdaq COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. It has real products. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Type a symbol or company name. Don't Get Greedy With Ocugen Stock, Says Analyst Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. It brings in no revenue. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. The chances of anything more are small but the rewards could be huge. Guys, theres no revenue here! In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. 1125 N. Charles St, Baltimore, MD 21201. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Ocugen Stock Is Not for the Faint of Heart - InvestorPlace Its all about choice. Companies will inevitably be optimistic about their prospects for success (at least publicly). Investors were hopeful that the small drugmaker would be able to win U.S. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. (See OCGN stock analysis on TipRanks). The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. If You Invested $1,000 In Ocugen Stock One Year Ago, Here's - Insider Theres even room for more lines. Keith Speights has no position in any of the stocks mentioned. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. Copy and paste multiple symbols separated by spaces. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. The potential synergies of such a union do not seem clear. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Even at around 40 cents per share, I would consider Ocugen stock overvalued. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market.